ABSTRACT
Recent studies have reported increases in early-onset cancer cases (diagnosed under age 50) and call into question whether the increase is related to earlier diagnosis from other medical tests and reflected by decreasing tumor-size-at-diagnosis (apparent effects) or actual increases in underlying cancer risk (true effects), or both. The classic Multi-Stage Clonal Expansion (MSCE) model assumes cancer detection at the emergence of the first malignant cell, although later modifications have included lag-times or stochasticity in detection to more realistically represent tumor detection requiring a certain size threshold. Here, we introduce an approach to explicitly incorporate tumor-size-at-diagnosis in the MSCE framework and account for improvements in cancer detection over time to distinguish between apparent and true increases in early-onset cancer incidence. We demonstrate that our model is structurally identifiable and provides better parameter estimation than the classic model. Applying this model to colorectal, female breast, and thyroid cancers, we examine changes in cancer risk while accounting for detection improvements over time in three representative birth cohorts (1950-1954, 1965-1969, and 1980-1984). Our analyses suggest accelerated carcinogenic events and shorter mean sojourn times in more recent cohorts. We further use this model to examine the screening impact on the incidence of breast and colorectal cancers, both having established screening protocols. Our results align with well-documented differences in screening effects between these two cancers. These findings underscore the importance of accounting for tumor-size-at-diagnosis in cancer modeling and support true increases in early-onset cancer risk in recent years for breast, colorectal, and thyroid cancer.
Significance This study models recent increases in early-onset cancers, accounting for both true factors contributing to cancer risk and those caused by improved detection. We show that while advancement in detection has led to earlier detection, our model estimates shorter sojourn times and more aggressive carcinogenic events for recent cohorts, suggesting faster tumor progression. Further, a counterfactual analysis using this model reveals the known statistically significant reduction in colorectal cancer incidence (supporting a robust modeling approach), likely due to screening and timely removal of precancerous polyps. Overall, we introduce an enhanced model to detect subtle trends in cancer risk and demonstrate its ability to provide valuable insights into cancer progression and highlight areas for future refinement and application.
Competing Interest Statement
Piero Dalerba is listed as a co-inventor on patents owned by the University of Michigan (US-07723112), Stanford University (US-09329170, US-09850483, US-10344094, US-11130813) and Columbia University (US-12115140-B2), and related to: 1) the discovery of surface markers for the differential purification of cancer stem cell populations from human malignancies; 2) the use of single-cell genomics technologies for the identification of pharmacological targets expressed in cancer stem cell populations; 3) the combination of anti-CD47 and anti-EGFR monoclonal antibodies for the treatment of human colon cancer; and 4) the use of inverse agonists of RAR/RXR signaling as anti-tumor agents against adenoid cystic carcinomas. Some of the patents listed above were licensed to pharmaceutical companies, resulting in the award of royalties and/or stock from Oncomed Pharmaceuticals, Quanticel Pharmaceuticals and Forty Seven Inc. (Gilead). Piero Dalerba recently owned stock of Eli Lilly and Company. Piero Dalerba's spouse is employed by Regeneron Pharmaceuticals Inc., and owns (or recently owned) stock of the following pharmaceutical companies: AbbVie, Amgen, AstraZeneca, Eli Lilly and Company, Gilead Sciences Inc., GlaxoSmithKline (GSK), Johnson & Johnson, Merck & Co., Novartis, Organon & Co., Pfizer, Teva Pharmaceutical Industries Ltd and Viatris. Chin Hur has served as a consultant for Guardant Health. Other authors declare no potential conflicts of interest.
Funding Statement
This work was supported by the National Institutes of Health (R01CA257971).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The study used ONLY openly available cancer incidence data originally located in the SEER registry dataset.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
All data produced in the present study are available upon reasonable request to the authors.
